Company Overview
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Why Investors Should Care
Revenue has grown at a 17.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.13.
Recent Developments
- Dec 2025 Revenue of $67.67M (+16.9% YoY); net profit $-412.69M.
- Trailing 12 Months Year-on-year growth — revenue -9.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 17.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.99% |
| 1 Year: | -9.50% |
Stock Price Performance
| 1 Year: | +9.12% |
| 6 Months: | +14.09% |
| 3 Months: | -11.77% |
| 1 Month: | +7.68% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 17.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 53.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NTLA Intellia Therapeutics, Inc. R2K | 13.04 | -3.70 | $1.82B | 0.00% | -59.74% | -56.34% | 16.99% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 6.21M | 5.92M | 7.32M | 6.67M | 7.47M | 7.68M | 7.41M | 7.88M | 10.43M | 11.12M | 10.62M | 10.94M | 12.92M | 16.26M | 22.22M | 6.59M | 6.45M | 6.55M | 7.20M | 11.25M | 14.03M | 13.27M | 12.61M | 13.59M | 11.99M | 28.93M | 6.96M | 9.11M | 16.63M | 14.24M | 13.78M | 15.05M |
| Operating Income | -1.20M | -3.42M | -3.30M | -5.49M | -6.69M | -6.95M | -7.70M | -10.82M | -12.95M | -16.02M | -15.88M | -24.71M | -22.43M | -23.59M | -24.10M | -20.75M | -23.81M | -27.46M | -25.33M | -29.77M | -33.05M | -33.03M | -28.10M | -42.40M | -46.42M | -69.02M | -71.99M | -144.25M | -98.30M | -105.53M | -111.96M | -132.33M | -131.11M | -114.00M | -139.04M | -144.77M | -120.81M | -110.00M | -111.48M | -100.53M |
| Net Income | -1.09M | -3.04M | -3.02M | -5.25M | -6.69M | -6.90M | -7.48M | -10.56M | -12.63M | -15.59M | -15.36M | -23.96M | -21.36M | -22.22M | -22.70M | -19.07M | -21.94M | -25.68M | -23.63M | -28.28M | -31.81M | -32.39M | -27.84M | -42.19M | -46.20M | -68.81M | -71.64M | -146.87M | -100.68M | -113.23M | -103.13M | -123.68M | -122.22M | -107.44M | -146.97M | -135.71M | -114.33M | -101.25M | -101.32M | -96.23M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.01 | -0.97 | -1.96 | -1.33 | -1.49 | -1.17 | -1.40 | -1.38 | -1.12 | -1.52 | -1.34 | -1.10 | -0.98 | -0.92 | -0.81 |
| R&D Expense | 1.37M | 1.97M | 3.46M | 4.38M | 5.22M | 7.42M | 7.86M | 11.33M | 13.43M | 15.56M | 17.48M | 21.17M | 22.49M | 23.47M | 23.24M | 19.92M | 23.71M | 25.46M | 27.51M | 31.73M | 34.65M | 37.77M | 39.76M | 38.23M | 39.28M | 58.88M | 60.49M | 133.09M | 90.20M | 96.65M | 97.12M | 115.28M | 113.70M | 111.85M | 114.21M | 123.38M | 108.43M | 97.03M | 94.75M | 80.74M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 16.48M | 26.12M | 30.43M | 43.10M | 57.99M | 33.05M | 52.12M | 36.27M | 57.88M | 67.67M |
| Operating Income | -13.41M | -32.16M | -69.56M | -90.87M | -106.37M | -136.58M | -267.85M | -458.16M | -515.29M | -534.26M | -440.99M |
| Net Income | -12.40M | -31.63M | -67.54M | -85.34M | -474.19M | -134.23M | -267.89M | -474.19M | -481.19M | -519.02M | -412.69M |
| Diluted EPS | - | - | - | - | - | -2.40 | -3.78 | -6.16 | -5.42 | -5.25 | -3.81 |
| R&D Expense | 11.17M | 31.84M | 67.65M | 89.11M | 108.41M | 150.41M | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2014 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 82.14M | 298.97M | 376.24M | 347.31M | 334.28M | 676.32M | 1.29B | 1.52B | 1.30B | 1.19B | 842.13M |
| Total Equity | 0 | 7.57M | -21.20M | 209.84M | 300.60M | 277.92M | 269.88M | 527.07M | 1.04B | 1.24B | 1.05B | 871.96M | 671.39M |
| Cash & Equivalents | - | 9.85M | 75.82M | 273.06M | 340.68M | 58.86M | 57.23M | 160.02M | 123.41M | 523.51M | 226.75M | 189.18M | 155.46M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | 284.53M | 250.81M | 319.06M | 170.73M |
| Current Liabilities | - | - | 10.70M | 30.73M | 31.36M | 40.57M | 35.63M | 64.25M | 125.83M | 126.55M | 115.21M | 110.85M | 103.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 36.11M | -65.28M | -61.26M | -103.24M | -49.91M | -225.03M | -333.29M | -394.09M | -348.88M | -394.74M |
| Investing Cash Flow | - | -6.17M | -10.09M | -260.78M | 25.18M | -214.49M | -550.78M | 160.31M | -31.35M | 125.57M | 228.03M |
| Financing Cash Flow | - | 167.30M | 142.98M | 40.22M | 76.43M | 371.78M | 736.69M | 582.96M | 130.32M | 185.75M | 131.49M |
| Capital Expenditure | -2.55M | -6.17M | -10.09M | -6.36M | -6.79M | -3.58M | -12.76M | -13.56M | -13.98M | -5.78M | -1.13M |
| Free Cash Flow | - | 29.94M | -75.37M | -67.61M | -110.03M | -53.50M | -237.79M | -346.85M | -408.07M | -354.66M | -395.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -195.2% | -266.3% | -298.6% | -246.8% | -235.5% | -810.4% | -879.0% | -1,420.5% | -923.1% | -651.7% |
| Net Margin % | - | -192.0% | -258.6% | -280.4% | -1,100.1% | -231.5% | -810.5% | -909.8% | -1,326.5% | -896.8% | -609.9% |
| ROE % | 58.5% | -15.1% | -22.5% | -30.7% | -175.7% | -25.5% | -25.8% | -38.4% | -45.8% | -59.5% | -61.5% |
| ROCE % | -18.8% | -12.0% | -20.2% | -29.6% | -35.6% | -22.3% | -22.9% | -32.9% | -43.5% | -49.5% | -59.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | ARK Investment Management, LLC | 10.38% | 14.51M | $193.34M |
| 2 | Blackrock Inc. | 8.70% | 12.16M | $161.98M |
| 3 | State Street Corporation | 4.95% | 6.92M | $92.24M |
| 4 | Vanguard Portfolio Management LLC | 4.45% | 6.22M | $82.93M |
| 5 | Shaw D.E. & Co., Inc. | 4.10% | 5.73M | $76.33M |
| 6 | Vanguard Capital Management LLC | 3.64% | 5.08M | $67.75M |
| 7 | Two Sigma Investments, LP | 3.37% | 4.71M | $62.71M |
| 8 | Regeneron Pharmaceuticals Inc | 2.65% | 3.70M | $49.34M |
| 9 | Geode Capital Management, LLC | 2.04% | 2.85M | $38.00M |
| 10 | UBS Group AG | 1.92% | 2.69M | $35.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NTLA
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNcjl4YmE3WHl0MERrejNnV2hDa0NKSmlQWWI5YUZ2a2U4cnB3ckFzRWNoWXBVNE1wRjh2Z3FyQ3Rrd3dGUkU2allaX0gwYzlwQ0V6VVM1WWhBcjB2SldtUmpGVEFTakR3djVDT2lISkxPOTRfdWdUS0F0M0JqSzdOeTRUeG8wcWNyX05ZN0…
More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQU1d4d2U3bGVQMnhYMjNwSWJUYkd0d2dmRERQZ25CaThhZlFlV0VXRFhmR2dxUHZrSmZDckJWMC1vMTZmUjB0ci1ZOThQR3BybkhoTmhVdWktb3BkOWczU3c0ZDFZSnZjcTR1Q0g3R2VxOFhJR3MxdG1HU3dsdW9CdTFDRUpreGhjRnhWSm…
Intellia Therapeutics (NTLA) Stock Looks Rich On Sales But Weak On Returns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPNHBuaHpNUGEzRngzZFFneWFFN0pCR1lZLTdWTjBTYmI5bnltSnBLODJ1RjBiSk94ZmRYdG9Zc254Q0pwTHpCa25oWkd1UmFxektnT0JpbXZKWGt0WDNhcGZzQ2Vjc2d0ZFFuLThIMWlkSTFzQ0RKVVpMTzJRcGE2MGRFSWU4ZU1oUVcwTm…
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNellLcjNuWUl4V1E4QTlQcklNWkF5N3FSR3ZvOUdGLUt3WEJTY0VxQm9MdzNncFBEdEZySlR4WDdaYzFONy1CenZCZFpOUTJBSk8zVlluQ3ZIRXNDWG5yVVpYRjc4dWhvRE51d0RqMVZ1Z0VQd3Vhbk55X25rSWpwaXZhUm1ET0tsTWEyNW…
$NTLA stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQT3l2cG8yTkFyS2xDcFhYS2tnQUM0ZUFxcE95ZHQ4SmRjQmRRZVVpd3pxamREamZjeU1IckJUZXAtU2c0eExGZGZTZ1RiUjQtY01KTko2UzVSUHhCN1czVEczTVpNX2ZXX1hyblRzdFVIRzlmVHE1MDBHdDMxaFZrVnpSMEt6dVFsWUxiNU…
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNNVhuZUJIcjFrUGtuTlZKY0U0RGJIaVd3ZXdqaXplZjdIaXVQMnFGb1RJTXNVV0dVQ0w4OXBjT0Y5blBSMTA0b0piU2FRcTBITjlUdzhPdGZITDhBZWVtNXBDazBIcDluRnBfZ1hOQzhSSjRfbVl6S1JaS252YmMtaGRrUzFka25VY3lzTn…
NTLA — Frequently Asked Questions
What is the current share price of Intellia Therapeutics, Inc. (NTLA)?
As of 2026-07-15 16:51 PDT, Intellia Therapeutics, Inc. (NTLA) trades at $13.04 on NasdaqGM. Its 52-week range is $8.04 to $27.98.
What is the market capitalisation of NTLA?
Intellia Therapeutics, Inc. (NTLA) has a market capitalisation of $1.82B on NasdaqGM.
What is the P/E ratio of NTLA?
NTLA trades at a trailing price-to-earnings (P/E) ratio of -3.70. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.59.
What is the return on equity (ROE) of NTLA?
NTLA has a return on equity (ROE) of -56.34%. Its return on capital employed (ROCE) is -59.74%.
Is NTLA a good stock to buy?
This page provides a data-driven analysis of Intellia Therapeutics, Inc. (NTLA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.